4.5 Article

Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer

Journal

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume 18, Issue 9, Pages 2492-2500

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-09-0362

Keywords

-

Funding

  1. NCI NIH HHS [R25 CA092049, R01 CA060117] Funding Source: Medline
  2. NIDDK NIH HHS [P30 DK084567] Funding Source: Medline

Ask authors/readers for more resources

Multiple genome-wide association studies have identified several susceptibility variants for colon cancer at 8q24. However, the functional roles of these variants have yet to be elucidated. Here, we evaluated the potential role of these markers in tumor progression and examined association with commonly observed structural abnormalities in this region, c-MYC amplification and chromosome fragility at FRA8C and FRA8D. We first replicated the previously reported association by testing 1,178 cases and 1,009 clinic-based controls with eight markers localized to three specific regions at 8q24. We observed significant associations with colon cancer risk with markers rs13254738 (ordinal odds ratio, 0.82; 95% confidence interval, 0.072-0.94; P-trend = 0.0037) and rs6983267 (ordinal odds ratio, 1.17; 95% confidence interval, 1.03-1.32, P-trend = 0.013). Survival analysis was done using a separate set of 460 cases to evaluate the clinical significance of these markers. Overall, univariate analysis did not detect survival differences for any of the markers. We also tested a subset of the 460 cases (n = 380) for structural abnormalities at or near the c-MYC locus using fluorescence in situ hybridization analysis. Furthermore, we evaluated a small number of cases homozygous for the rs6983267 alleles to test for differences in fragile site induction. None of the 8q markers correlated with amplification at the c-MYC locus as detected by fluorescence in situ hybridization, and no clear pattern of breakage was observed at the FRA8C and FRA8D sites. In this study, we confirm the association for several single nucleotide polymorphisms at 8q24 in colon cancer but have not detected any structural role relating to c-MYC amplification or chromosomal fragility. Finally, these risk alleles do not seem to be associated with survival. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2492-500)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Susan L. Slager, Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp, Fatima Abbasi, Neil E. Kay, Celine M. Vachon, James R. Cerhan, James B. Johnston, Timothy G. Call, Kari G. Rabe, Geffen Kleinstern, Nicholas J. Boddicker, Aaron D. Norman, Sameer A. Parikh, Jose F. Leis, Versha Banerji, Danielle M. Brander, Martha Glenn, Alessandra Ferrajoli, Karen Curtin, Esteban Braggio, Tait D. Shanafelt, Mary L. McMaster, J. Brice Weinberg, Curtis A. Hanson, Neil E. Caporaso

Summary: The study investigated the incidence and natural history of MBL in relatives from CLL families, finding that low-count MBL may precede progression to CLL with a higher transformation rate in these families. Furthermore, the study estimated an annual progression rate from low-count MBL to CLL that exceeds that in the general population.

BLOOD (2021)

Article Oncology

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma

Alessia Castellino, Aung M. Tun, Yucai Wang, Thomas M. Habermann, Rebecca L. King, Kay M. Ristow, James R. Cerhan, David J. Inwards, Jonas Paludo, Stephen M. Ansell, Thomas E. Witzig, Grzegorz S. Nowakowski

Summary: Primary GI MCL is rare but has similar outcomes as secondary GI MCL. Less aggressive frontline treatment is reasonable for primary GI MCL, with the impact of GI involvement on treatment selection but not on outcome. It remains uncertain whether more aggressive treatment can lead to improved outcomes.

BLOOD CANCER JOURNAL (2021)

Article Oncology

Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma

Mark Liebow, Melissa C. Larson, Carrie A. Thompson, Grzegorz S. Nowakowski, Timothy G. Call, William R. Macon, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan

Summary: The study found that regular use of low-dose aspirin may reduce the risk of non-Hodgkin lymphoma, while other NSAIDs and statins showed no association with NHL risk.

INTERNATIONAL JOURNAL OF CANCER (2021)

Article Oncology

High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)

Joshua C. Pritchett, Zhi-Zhang Yang, Hyo Jin Kim, Jose C. Villasboas, Xinyi Tang, Shahrzad Jalali, James R. Cerhan, Andrew L. Feldman, Stephen M. Ansell

Summary: AITL is an aggressive lymphoid malignancy with a unique tumor microenvironment characterized by a minority population of malignant TFH cells and a diverse infiltrate of immune cells. Non-malignant populations within the TME, such as B cells and CD8+ T cells, are increasingly recognized for their potential role in AITL biology. These non-malignant populations exhibit specific expression patterns that may contribute to the understanding of AITL pathogenesis.

LEUKEMIA (2022)

Editorial Material Hematology

A (modifiable) way to better Hodgkin lymphoma survivorship?

James R. Cerhan

Summary: In this article, Williams et al. provide a clearer perspective on the additional burden of neurocognitive, psychosocial, and quality of life impairments faced by long-term survivors of childhood Hodgkin lymphoma. The authors also identify potentially modifiable factors that could help prevent or reduce adverse outcomes.

BLOOD (2022)

Article Oncology

B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS

Sophia S. Wang, Claire M. Vajdic, Martha S. Linet, Susan L. Slager, Jenna Voutsinas, Alexandra Nieters, Delphine Casabonne, James R. Cerhan, Wendy Cozen, Graciela Alarcon, Otoniel Martinez-Maza, Elizabeth E. Brown, Paige M. Bracci, Jennifer Turner, Henrik Hjalgrim, Parveen Bhatti, Yawei Zhang, Brenda M. Birmann, Christopher R. Flowers, Ora Palliel, Elizabeth A. Holly, Eleanor Kane, Dennis Weisenburger, Marc Maynadie, Pierluigi Cocco, Lenka Foretova, Elizabeth Crabb Breen, Qing Lan, Angela Brooks-Wilson, Anneclaire J. De Roos, Martyn T. Smith, Eve Roman, Paoloa Boffetta, Anne Kricker, Tongzhang Zheng, Christine F. Skibola, Jacqueline Clavel, Alain Monnereau, Stephen J. Chanock, Nathaniel Rothman, Yolanda Benavente, Patricia Hartge, Karin E. Smedby

Summary: This study suggests that polygenic risk scores (PRS) constructed from currently known subtype-specific loci may not capture biological pathways shared with autoimmune conditions. Targeted genetic screening (PRS) among populations with autoimmune conditions may help identify individuals at highest risk for DLBCL and enable early detection.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Oncology

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts

Sanjal H. Desai, Levi D. Pederson, Betsy Laplant, Raphael Mwangi, Matthew J. Maurer, Jason R. Young, William R. Macon, Rebecca L. King, Yucai Wang, James R. Cerhan, Andrew L. Feldman, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski

Summary: This study found that PET2 after two cycles of chemotherapy can predict the risk of disease progression and death in patients with diffuse large B cell lymphoma. PET2-guided risk-adapted strategies may improve outcomes for these patients.

BLOOD CANCER JOURNAL (2022)

Article Oncology

Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care

Surbhi Sidana, Cristine Allmer, Melissa C. Larson, Amylou Dueck, Kathleen Yost, Rahma Warsame, Gita Thanarajasingam, James R. Cerhan, Jonas Paludo, S. Vincent Rajkumar, Thomas M. Habermann, Grzegorz S. Nowakowski, Yi Lin, Morie A. Gertz, Thomas Witzig, Angela Dispenzieri, Wilson Gonsalves, Stephen M. Ansell, Carrie A. Thompson, Shaji K. Kumar

Summary: Patients treated on CTs reported similar QoL and quality of care compared to the non-CT group, but both groups experienced increasing financial burden over time.

JCO ONCOLOGY PRACTICE (2022)

Review Hematology

Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma

Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn

Summary: Comparative effectiveness studies using real-world data can provide complementary evidence on treatment effectiveness. By balancing baseline covariates using propensity score methods, closely matched patient-level cohorts can be generated for robust comparative analyses.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Hematology

Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma

Juan Pablo Alderuccio, Isildinha M. Reis, Thomas M. Habermann, Brian K. Link, Catherine Thieblemont, Annarita Conconi, Melissa C. Larson, Luciano Cascione, Wei Zhao, James R. Cerhan, Emanuele Zucca, Izidore S. Lossos

Summary: The study developed and validated a new prognostic index, the Revised mucosa-associated lymphoid tissue International Prognostic Index (Revised MALT-IPI), which is centered on disease characteristics and provides robust risk stratification, identifying a group of patients characterized by earlier progression of EMZL.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Oncology

Physical activity and the risk of non-Hodgkin lymphoma subtypes: A pooled analysis

Terry Boyle, Geffen Kleinstern, Paige M. Bracci, James R. Cerhan, Yolanda Benavente, Delphine Casabonne, Brian C-H Chiu, Thomas M. Habermann, Elizabeth A. Holly, Mark Liebow, Aaron Norman, Ora Paltiel, Dennis Robinson, Nathaniel Rothman, Rania Abu Seir, Susan L. Slager, Paul J. Villeneuve, Sophia S. Wang, Dennis D. Weisenburger, John J. Spinelli

Summary: This study, which pooled data from nine case-control studies, found that moderate-to-vigorous intensity physical activity can reduce the risk of non-Hodgkin lymphoma.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Hematology

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis

Sanjal H. Desai, Raphael Mwangi, Wern Lynn Ng, Rebecca L. King, Matthew J. Maurer, James R. Cerhan, Andrew L. Feldman, Umar Farooq, Eric Mou, Thomas M. Habermann, Carrie A. Thompson, Yucai Wang, Thomas E. Witzig, Grzegorz S. Nowakowski

Summary: This observational study found that patients with DLBCL who underwent CNB had poor-risk features, worse outcomes, and inadequate tissue for molecular analyses compared to those who underwent EB. The increasing tissue requirements of biomarker-driven clinical trials may result in the exclusion of high-risk DLBCL patients who need novel agents.

BLOOD ADVANCES (2022)

Letter Oncology

The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis

Sameer A. Parikh, Sara J. Achenbach, Kari G. Rabe, Aaron D. Norman, Nicholas J. Boddicker, Janet E. Olson, Timothy G. Call, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Esteban Braggio, Curtis A. Hanson, Susan L. Slager, Tait D. Shanafelt

BLOOD CANCER JOURNAL (2022)

Article Oncology

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

Cristina Correia, Matthew J. J. Maurer, Samantha J. J. McDonough, Paula A. A. Schneider, Paige E. E. Ross, Anne J. J. Novak, Andrew L. L. Feldman, James R. R. Cerhan, Susan L. L. Slager, Thomas E. E. Witzig, Bruce W. W. Eckloff, Hu Li, Grzegorz S. S. Nowakowski, Scott H. H. Kaufmann

Summary: The identification of follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. In a study on newly diagnosed FLs, BCL2 mutations with high variant allele frequency (VAF) were found to be associated with increased transformation risk and shorter event-free survival. However, other sequenced genes did not contribute significantly to the prognostic value of the panel. Nonsynonymous BCL2 mutations with VAF = 20% were consistently associated with decreased event-free survival and overall survival.

BLOOD CANCER JOURNAL (2023)

Article Environmental Sciences

Modeling historic neighborhood deprivation and non-Hodgkin lymphoma risk

Joseph Boyle, Mary H. Ward, James R. Cerhan, Nathaniel Rothman, David C. Wheeler

Summary: Many studies have found associations between neighborhood deprivation and disease, emphasizing the importance of social determinants of health. However, when studying diseases with long latency periods such as cancers, considering the timing of exposures for deprivation becomes more important.

ENVIRONMENTAL RESEARCH (2023)

No Data Available